Type of Submission
Poster
Keywords
Oncology, infection, prophylaxis
Proposal
Guidelines clearly outline the prophylactic measures prescribers should take to prevent infections in their patients with cancer. One of the leading causes mortality in cancer patients is microbial infection. Adhering well to evidence-based guidelines improves both cost outcomes for healthcare systems and health outcomes for patients. Current guidelines available today: NCCN, AGIHO/DGHO, MASCC/ISOO, ACS, and ASCO/IDSA.
OBJECTIVE 1: To assess prescriber adherence to antimicrobial guidelines in low- to medium-risk patients with cancer. ● Null Hypothesis of Objective 1: Prescribers are adherent to antimicrobial prophylaxis guidelines (greater than 80% prescribing practices). ● Alternative Hypothesis of Objective 1: Prescribers are not adherent to antimicrobial prophylaxis guidelines (less than or equal to 80% prescribing practices).
OBJECTIVE 2: To assess the incidence of microbial infections in low- to medium-risk patients with cancer. ● Null Hypothesis of Objective 2: There is not an increased incidence of infections in low- to medium-risk patients with cancer who did not receive antimicrobial prophylaxis compared to those who did. ● Alternative Hypothesis of Objective 2: There is an increased incidence of infections in low- to medium-risk patients with cancer who did not receive antimicrobial prophylaxis compared to those who did.
A retrospective chart analysis was utilized to assess infection prophylaxis in low- to medium- risk cancer patients at Kettering Health Cancer Center following IRB approval. Patients’ charts were reviewed from the electronic medical record to assess prescriber adherence to prophylaxis guidelines as well as incidence of infection in the patient.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Publication Date
2024
Prescribers' Adherence to Infection Prophylaxis Guidelines in a Community Oncology Center
Guidelines clearly outline the prophylactic measures prescribers should take to prevent infections in their patients with cancer. One of the leading causes mortality in cancer patients is microbial infection. Adhering well to evidence-based guidelines improves both cost outcomes for healthcare systems and health outcomes for patients. Current guidelines available today: NCCN, AGIHO/DGHO, MASCC/ISOO, ACS, and ASCO/IDSA.
OBJECTIVE 1: To assess prescriber adherence to antimicrobial guidelines in low- to medium-risk patients with cancer. ● Null Hypothesis of Objective 1: Prescribers are adherent to antimicrobial prophylaxis guidelines (greater than 80% prescribing practices). ● Alternative Hypothesis of Objective 1: Prescribers are not adherent to antimicrobial prophylaxis guidelines (less than or equal to 80% prescribing practices).
OBJECTIVE 2: To assess the incidence of microbial infections in low- to medium-risk patients with cancer. ● Null Hypothesis of Objective 2: There is not an increased incidence of infections in low- to medium-risk patients with cancer who did not receive antimicrobial prophylaxis compared to those who did. ● Alternative Hypothesis of Objective 2: There is an increased incidence of infections in low- to medium-risk patients with cancer who did not receive antimicrobial prophylaxis compared to those who did.
A retrospective chart analysis was utilized to assess infection prophylaxis in low- to medium- risk cancer patients at Kettering Health Cancer Center following IRB approval. Patients’ charts were reviewed from the electronic medical record to assess prescriber adherence to prophylaxis guidelines as well as incidence of infection in the patient.
